Skip to main content

Table 3 Patient characteristics of the study population

From: A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

Pt Age Gender PS Stage at diagnosis Prevaccination therapy Extent of disease at first vaccination
1 61 M 1 II SX2 Lung and mediastinal LN metastasis
2 66 F 0 III SX2 NED
3 40 M 0 III SX3, IFN-α, IL-2 NED
4 71 M 1 IV SX1, IFN-α Lung and abdominal wall metastasis
5 65 M 1 III SX2, IL-2, RX1 NED
6 69 M 0 III SX4, RFAX2 Lung and liver metastasis
  1. Abbreviations: Pt = patient; PS = performance status; NED = no evidence of disease; M = male; F = female; LN = lymph nodes; S = surgery; IFN-α = Interferon-α; IL-2 = Interleukin-2; Rx = radiation; RFA = radiofrequency ablation.